Clarus Therapeutics Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (ticker: CRXT) is a United States-based specialty pharmaceutical company listed on a NYSE/NASDAQ venue, with a business profile centered on men’s health and testosterone replacement therapy. The company’s roots go back to 2004, when Clarus Therapeutics was founded in Northbrook, Illinois. Its current corporate structure was created in September 2021, when the legacy Clarus business completed a merger with Blue Water Acquisition Corp., a SPAC transaction that resulted in the renaming of the combined entity to Clarus Therapeutics Holdings, Inc. The company remains headquartered in Northbrook, Illinois, keeping its operational base in the U.S. Midwest. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312522092120/d288074d10k.htm)) From a business standpoint, Clarus is a focused commercialization-stage pharmaceutical company whose core and historically sole revenue driver has been JATENZO, an oral testosterone replacement therapy. According to SEC disclosures, JATENZO was launched commercially in February 2020 after FDA approval in March 2019. Management has described it as the first and only oral TRT of its kind approved by the FDA, which gives Clarus a differentiated position in a market dominated by injectable and topical testosterone products. The company’s sales have been reported as exclusively within the United States, so the commercial footprint is highly concentrated and domestically oriented. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312522092120/d288074d10k.htm)) In competitive terms, Clarus operates in a crowded therapeutic area where scale, physician familiarity, payer access, and patient adherence all matter. Its strategic advantage lies in formulation differentiation rather than broad product breadth. An oral administration profile can be attractive for certain patients and prescribers, but the company also faces the classic risks of a single-product specialty pharma model: concentration risk, regulatory dependence, and execution risk in a market with entrenched alternatives. SEC filings also note recurring operating losses and periodic disclosures around going-concern considerations and the need for additional financing, underscoring the company’s financially fragile, situation-specific nature. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312521366306/d262025d424b3.htm)) Recent corporate context remains tied to U.S. SEC reporting and insider activity, including Form 4 filings that reflect the movement of stock ownership by officers, directors, and large holders. For investors, that makes CRXT a name that is best assessed through a special-situations lens: product commercialization, balance-sheet resilience, and the sustainability of JATENZO’s U.S. revenue base matter more than portfolio diversification. In short, Clarus Therapeutics Holdings, Inc. is a small-cap U.S. specialty pharma company with a niche oral TRT franchise, a Northbrook, Illinois headquarters, and a high-risk/high-uncertainty investment profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001817944/000101376221000025/xslF345X03/ownership.xml?utm_source=openai))